Fakultni nemocnice Olomouc

Running trials

• Not yet recruiting

  A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations

  NCT07612657· Phase 3· Source

• Recruiting

  BIO|STREAM.CSP Study

  NCT07393009· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Source

• Recruiting

  Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System

  NCT07018648· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

  NCT06680817· Source

• Recruiting

  Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening

  NCT06549725· Source

• Enrolling by invitation

  A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients

  NCT06445673· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Source

• Recruiting

  A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  NCT05980806· Phase 2· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Recruiting

  A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

  NCT06072482· Phase 4· Source

• Active, not recruiting

  A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

  NCT05668988· Phase 3· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Active, not recruiting

  Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

  NCT05043103· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Source

• Active, not recruiting

  A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

  NCT04194944· Phase 3· Source

• Active, not recruiting

  Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

  NCT03366545· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Atrial fibrillation1 recruiting
• Colorectal cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Lung cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Recruiting

  Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

  NCT05665608· Source

• Completed

  BIOSTREAM.HF HeartInsight

  NCT05761249· Source

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Source

• Completed

  Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

  NCT05458856· Phase 3· Source

• Terminated

  A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

  NCT05256381· Phase 2· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Source

• Terminated

  Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

  NCT04892446· Phase 2· Source

• Completed

  A Study of Surgical Interventions in Fistulizing Conditions

  NCT04940611· Source

• Completed

  A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

  NCT04785820· Phase 2· Source

• Active, not recruiting

  A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

  NCT04657991· Phase 3· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Source

• Completed

  TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants

  NCT05236777· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Source

• Completed

  Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

  NCT03173560· Phase 2· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· Source

• Completed

  A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

  NCT02576431· Phase 2· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source